ArticleCells2020
Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.
Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis.Technology in cancer research & treatmentPooled it
- 20 years of taxane therapy in prostate cancer - the past, present and future.Nature reviews. Urology · 2026Review
- Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy.International journal of molecular sciences · 2025Article
- Circulating tumour cells for the prediction of the response to radiation therapy in prostate cancer.The British journal of radiology · 2025Review
- A narrative review of the current state of circulating tumor cells in prostate cancer diagnostic.Hellenic urology · 2025Article
- The role of neuroendocrine differentiation in treatment resistance of prostate cancer and intervention strategies.Frontiers in oncology · 2025Review
- The yin and yang of chromosomal instability in prostate cancer.Nature reviews. Urology · 2024Review
- Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer.iScience · 2023Article
- Beyond Prostate Cancer: An Androgen Receptor Splice Variant Expression in Multiple Malignancies, Non-Cancer Pathologies, and Development.Biomedicines · 2023Review
- Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer.Cell reports. Medicine · 2023Article
- Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer.Clinical and translational science · 2022Article
- Insights into Circulating Tumor Cell Clusters: A Barometer for Treatment Effects and Prognosis for Prostate Cancer Patients.Cancers · 2022Review
- Androgen receptor variant-7 regulation by tenascin-c induced src activation.Cell communication and signaling : CCS · 2022Article
- A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis.Cancers · 2022Review
- A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer.Cancers · 2020Article
- A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer.Diagnostics (Basel, Switzerland) · 2020Article
- Molecular mechanisms of docetaxel resistance in prostate cancer.Cancer drug resistance (Alhambra, Calif.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen receptor (AR) signaling remains crucial in castration-resistant prostate cancer (CRPC). Since it is also essential in immune cells, we studied whether the expression of AR full-length
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.